Expression and clinical significance of B-cell lymphoma 2 (BCL-2) in hyperleukocytic acute myeloid leukemia.
10.7534/j.issn.1009-2137.2013.04.008
- Author:
Min WANG
1
;
Li-Ru WANG
;
Jian-Ying CUI
;
He-Bing ZHOU
Author Information
1. Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
- Publication Type:Journal Article
- MeSH:
Case-Control Studies;
Female;
Flow Cytometry;
Humans;
Leukemia, Myeloid, Acute;
blood;
pathology;
Male;
Middle Aged;
Proto-Oncogene Proteins c-bcl-2;
blood
- From:
Journal of Experimental Hematology
2013;21(4):851-856
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the role of B-cell lymphoma 2 (BCL-2) in pathogenesis of hyperleukocytic acute myeloid leukemia (AML). The levels of intracellular BCL-2 in 48 AML patients were detected by flow cytometry (FCM). Serum levels of BCL-2 in 40 AML patients were measured by enzyme-linked immunosorbent assay (ELISA). The results showed that the serum levels of BCL-2 in hyperleukocytic AML and non-hyperleukocytic AML patients were significantly higher than that in normal controls (P < 0.05), but intracellular BCL-2 levels were not significantly different, as compared with normal controls (P > 0.05). There were no difference of intracellular and serum BCL-2 levels between hyperleukocytic and non-hyperleukocytic AML patients (P > 0.05). The serum and intracellular levels of BCL-2 between hyperleukocytic AML, non-hyperleukocytic AML patients and normal controls were not statistically correlated. It is concluded that leukemic cells in AML patients produce and secrete too much BCL-2, which may be involved in the pathogenesis of leukemia disease. However, the anti-apoptosis effect of BCL-2 has no significant impact on the pathogenesis of hyperleukocytic AML.
